

## > TEAM



PhD. José Biurrun  
Manresa  
CEO  
[in](#)



PhD. Christian  
Mista  
CSO  
[in](#)

"More than 25 year in  
neuroscience pain  
research"



MSc. Silvio  
Laugero  
CTO  
[in](#)




MSc. Leandro  
Mayrata  
COO  
[in](#)



MSc. Azul Quiroga  
Business Advisor  
[in](#)

## > PROBLEM THAT WE FACE


- **Measuring pain** is subjective and reliant on the patient's ability to communicate their experience in clinical practice.
- Challenging for patients with chronic pain conditions, such as **diabetic peripheral neuropathy** which is the strongest **risk factor for diabetic foot ulceration** leading to amputation.
- Early diagnosis and follow-up are essential for a good prognosis.



1 OF 2 DIABETES PATIENTS  
SUFFER PAIN DISORDERS

## > OUR SOLUTION

- We develop a platform that provides **objective assessment** of the state of **nerve pathways that transmit pain information**, offering a quantitative analysis of pain.



## > NEXT MILESTONES

### NOW

- Alpha-prototype .
- Pilot trial with healthy volunteers.

### NEXT 18 MONTH

- Beta-prototype.
- Pilot trial with patients.
- IP registration in EEUU, CE and others countries.
- FDA C510k pre-meeting.
- Final clinical trial initiated.

## > TECHNOLOGY (HOW?)

Our **Patented** technology comprises:

- Radiofrequency (RF) **stimulation system** which specifically targets pain-transmitting receptors.
- **Brain activity recording system** that automatically analyses the response to this stimulus.

## > COMPETITIVE EDGE

- ++ More **accurate** than conventional subjective scales.
- ++ More **specific** than existing nerve conduction test.
- ++ **Point-of-care** / no especial setup is needed.

## > IMPACT

**Improve patient outcomes** by enabling doctors to make **more informed and accurate diagnoses**, tailor treatments to individual needs, and monitor patients' progress more effectively.